105538-07-6

Basic information

• Product Name: 3-AMINO-6-(4-FLUOROPHENYL)PYRIDAZINE
• Synonyms: 3-AMINO-6-(4-FLUOROPHENYL)PYRIDAZINE;3-Pyridazinamine, 6-(4-fluorophenyl)-;6-(4-Fluorophenyl)pyridazin-3-amine, 1-(6-Aminopyridazin-3-yl)-4-fluorobenzene;6-(4-fluorophenyl)pyridazin-3-aMine
• CAS NO: 105538-07-6
• Molecular Formula: C₁₀H₈FN₃
• Molecular Weight: 189.19
• Mol File: 105538-07-6.mol

Chemical Properties

• Melting Point: 165-168 °C
• Boiling Point: 398.024 °C at 760 mmHg
• Flash Point: 194.518 °C
• Appearance: /
• Density: 1.281 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• PKA: 4.67±0.10(Predicted)
• CAS DataBase Reference: 3-AMINO-6-(4-FLUOROPHENYL)PYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-6-(4-FLUOROPHENYL)PYRIDAZINE(105538-07-6)
• EPA Substance Registry System: 3-AMINO-6-(4-FLUOROPHENYL)PYRIDAZINE(105538-07-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 105538-07-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Amino-6-(4-fluorophenyl)pyridazine is used as a key intermediate in the synthesis of pharmaceutical compounds for its versatile chemical reactivity and potential to interact with biological targets, contributing to the development of new drugs with specific therapeutic effects.
Used in Agrochemical Development:
In the agrochemical industry, 3-Amino-6-(4-fluorophenyl)pyridazine is utilized as a building block in the creation of novel agrochemicals, leveraging its chemical properties to enhance crop protection and yield.
Used in Medicinal Chemistry and Drug Discovery:
3-Amino-6-(4-fluorophenyl)pyridazine is employed as a molecular scaffold in medicinal chemistry for its unique structure, which allows for the design of compounds with specific binding affinities to biological targets, facilitating drug discovery and the advancement of therapeutic agents.

InChI:InChI=1/C10H8FN3/c11-8-3-1-7(2-4-8)9-5-6-10(12)14-13-9/h1-6H,(H2,12,14)

Upstream product

• 1765-93-1 4-fluoroboronic acid 
• 187973-60-0 6-iodopyridazine-3-amine 
• 58897-67-9 6-(p-fluorophenyl)-3(2H)-pyridazinone 
• 66548-52-5 3-chloro-6-(4-fluorophenyl)pyridazine 
• 5469-69-2 6-chloro-pyridazin-3-ylamine 
• 88490-21-5 [6-(4-Fluoro-phenyl)-pyridazin-3-yl]-hydrazine 

Relevant articles and documents

Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization

A novel class of bivalent ligands targeting putative protease-activated receptor (PAR) heteromers has been prepared based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of the PAR1 antagonist RWJ-58259 containing alkyne adapters were connected via cycloaddition reactions to azide-capped polyethylene glycol (PEG) spacers attached to imidazopyridazine-based PAR2 antagonists. Initial studies of the PAR1-PAR2 antagonists indicated that they inhibited G alpha q-mediated calcium mobilization in endothelial and cancer cells driven by both PAR1 and PAR2 agonists. Compounds of this novel class hold promise for the prevention of restenosis, cancer cell metastasis, and other proliferative disorders.

IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY

The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, dis

Mild and direct access to 7-substituted-4-trifluoromethylpyrimido[1,2- b ]pyridazin-2-one systems

New and efficient methods for the synthesis of 7-substituted-4- trifluoromethylpyrimido[1,2-b]pyridazin-2-one derivatives using either two-step Suzuki/heterocyclization, or two-step heterocyclization/substitution sequences are developed. A variety of substituted products are obtained in good to excellent yields from 3-amino-6-chloropyridazine and ethyl 4,4,4-trifluorobut-2- ynoate. Georg Thieme Verlag Stuttgart · New York.

A short and straightforward approach towards 6-amino and 6-aminoalkyl thiazolo[4,5-c]pyridazines

A facile and efficient synthesis of 6-amino and 6-aminoalkyl thiazolo[4,5-c]pyridazines is reported. The key step for the construction of this novel bicyclic scaffold was the reaction between 3-amino-4-bromopyridazine derivatives and alkylisothiocyanates.

Microwave-enhanced synthesis of 2,3,6-trisubstituted pyridazines: Application to four-step synthesis of gabazine (SR-95531)

Microwave-enhanced, highly efficient protocols for the synthesis of synthetically and biologically important 2,3,6-trisubstituted pyridazine architectures have been developed by sequential amination/Suzuki coupling/alkylation reactions. This powerful strategy is an economical and highly chemoselective protocol for the synthesis of diversified pyridazines. The total synthesis of gabazine (SR-95531) has been achieved using a versatile strategy in four steps and 73% overall yield.

A new approach towards the synthesis of 3-amino-6- (hetero)arylpyridazines based on palladium catalyzed cross-coupling reactions

The synthesis of 3-amino-6-(hetero)arylpyridazines via palladium catalyzed cross-coupling reactions (Suzuki, Stille) on 3-amino-6- chloropyridazine (1a) and 3-amino-6-iodopyridazine (1b) has been investigated. Comparison of the results shows that there is

Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists

We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.